Lacosamide for children with paroxysmal kinesigenic dyskinesia

Furukawa, Gen; Negishi, Yutaka; Takeuchi, T. T.; Ishihara, Naoko; Okumura, Akihisa

doi:10.1016/j.braindev.2020.04.009

Cited by 7 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with previous reports, LCM in the presented case provided prompt and complete PKD control [ 3 , 4 ]. In contrast, however, to a case series of 7 MS patients [ 1 ] where SPD did not recur after 4 weeks of treatment, the discontinuation of LCM led to a severe relapse which responded to drug reinitiation.…”

supporting

confidence: 91%

“…Since the patient was receiving desmopressin, carbamazepine was avoided because its combined use with desmopressin might increase the risk of adverse effects (i.e., hyponatremia). Prompted by the positive experience with LCM in four cases of idiopathic PKDs and in one case of SPD attributed to neuromyelitis optica spectrum disorder (NMOSD) [ 3 , 4 ], LCM (gradually up-titrated to 300 mg/24 h per os) was administered and significantly reduced the frequency of the attacks ( Figure 1E ). Five weeks later, LCM was discontinued, which led to a severe relapse.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Multiple Sclerosis-Related Paroxysmal Kinesigenic Dyskinesia: Long Term, Favorable Response to Lacosamide

Poulidou

Spilioti

Moschou

et al. 2022

JMD

View full text Add to dashboard Cite

supporting

confidence: 91%

mentioning

confidence: 99%

Multiple Sclerosis-Related Paroxysmal Kinesigenic Dyskinesia: Long Term, Favorable Response to Lacosamide

Poulidou

Spilioti

Moschou

et al. 2022

JMD

View full text Add to dashboard Cite

“…18 Of note, a recent study finds that lacosamide may also be effective in PKD. 19 Impaired inhibition likely plays a role not only in a variety of pediatric movement disorders, but also in epilepsy. 20,21 While the specific effects of lacosamide on motor inhibition in children with epilepsy is unknown, lacosamide does decrease motor cortex excitability in adults.…”

Section: Discussionmentioning

confidence: 99%

Lacosamide-Induced Dyskinesia in Children With Intractable Epilepsy

et al. 2020

View full text Add to dashboard Cite

Lacosamide, an antiepileptic drug prescribed for children with refractory focal epilepsy, is generally well tolerated, with dose-dependent adverse effects. We describe 4 children who developed a movement disorder in conjunction with the initiation and/or uptitration of lacosamide. Three patients developed dyskinesias involving the face or upper extremity whereas the fourth had substantial worsening of chronic facial tics. The patients all had histories suggestive of opercular dysfunction: 3 had seizure semiologies including hypersalivation, facial and upper extremity clonus while the fourth underwent resection of polymicrogyria involving the opercula. Onset, severity, and resolution of dyskinesias correlated with lacosamide dosing. These cases suggest that pediatric patients with dysfunction of the opercular cortex are at increased risk for developing drug-induced dyskinesias on high-dose lacosamide therapy. Practitioners should be aware of this potential side effect and consider weaning lacosamide or video electroencephalography (EEG) for differential diagnosis, particularly in pediatric patients with underlying opercular dysfunction.

show abstract

“…In an animal model of PKD, both CBZ and lacosamide, which preferentially bind to inactivated Na v channels (Kuo et al, 1997), could prevent the generation of cerebellar SD and alleviate dyskinesia attack. Remarkably, patients with PKD also respond well to CBZ (Li et al, 2013), lamotrigine (Li et al, 2016), and lacosamide (Furukawa et al, 2020). It is therefore most likely that effective medical treatments for PKD depend on preventing the induction of cerebellar SD.…”

Section: Cellmentioning

confidence: 99%